PULMOTECT’S MANAGEMENT TEAM includes the lead inventors of the technology as well experienced business leaders. In collaboration with leading academic institutions, this team is well positioned to achieve the milestones and transition our products from the clinic to the market.


President and Chief Operating Officer

Dr. Scott is a co-founder of the company and has helped lead the initial technology out of the lab and into the clinic. Prior to his industry role, his academic experience focused on vesicular traffic, airway inflammation and infection. He serves as the PI on multiple grant awards, including the Cancer Prevention Research Institute of Texas (CPRIT) and Texas Emerging Technology Fund (TETF) awards from the State of Texas and seven Small Business Innovative Research (SBIR) awards. He is a regular reviewer of SBIR grant applications for the NIH. He concurrently received his PhD in Biochemistry and Cell Biology from Rice University and his MBA from University of Houston.

Rena Johnson, PH.D.

Project Manager

Rena Johnson is a Project Manager at Pulmotect. She joined the company in May 2018. Dr. Johnson received her Ph.D. in Biology from the University of Kiel, Germany in 2011. She moved to the US for a postdoctoral training at the Center for Lung Biology at the University of Washington, Seattle and at the Women’s Guild Lung Institute at Cedars-Sinai Medical Center, Los Angeles with Dr. Peter Chen. During her postdoctoral training, her research focused on the role of the lung epithelium in acute lung injury, especially in the response to influenza infection with particular interest in the role of syndecan-1, the major proteoglycan expressed by epithelial cells in the lung.  She has strong interest in translating innovation from the lab bench to novel bio-medical solutions that can ultimately improve patient’s health.


Head, Clinical Operations and Consultant

Dr. Schaumberg has more than 30 years of drug development expertise, including experience with global pharmaceutical organizations, biotechnology companies and clinical research organizations. His past roles include Vice President level positions in Biotech as Senior Vice President, Clinical Operations of Agennix AG as well as Vice President level positions in the clinical research organizations PRA International and Inveresk. Prior to Inveresk, he held a variety of clinical development and project management roles with Glaxo, Parke-Davis and Valentis. While at Glaxo, he was involved in the clinical development programs of Serevent®, a long acting beta agonist, and Flovent®, an inhaled corticosteroid, for the treatment of asthma. Dr. Schaumberg received his Ph.D. from the University of Iowa (U.S.) in Medicinal Chemistry and Natural Products, and his Bachelor of Pharmacy from Washington State University (U.S.).